Skip to main content


Fig. 6 | Clinical Epigenetics

Fig. 6

From: Epigenetic synergy between decitabine and platinum derivatives

Fig. 6

Decitabine and carboplatin modulate histones and methyl-binding proteins. We treated YB5 with 25 nM decitabine and/or 25 μM carboplatin for 4 days. Subsequently, we performed chromatin immunoprecipitation in YB5 controls and treated cells with antibodies against H3K4me3 (a), H3K9Ac (b), MBD2 (c), and MECP2A (d). We analyzed the abundance of the activation histone marks (H3K4me3, H3K9Ac) and methyl-binding proteins (MBD2, MECP2) at promoters of CMV, p16, RARB2, ESR1, and MLH1. Statistical significance of Bonferroni-corrected t tests is shown by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001)

Back to article page